Table 1.
Relationship between HPV and p16 positivity and clinic parameters.
| Both positive | Only one positive | Both negative | p | |
|---|---|---|---|---|
| Age | 58.83 (12.281) | 57.41 (10.063) | 60.70 (10.909) | 0.520 |
| Differentiation | 0.840 | |||
| Well | 2 (33.3 %) | 8 (47.1 %) | 36 (53.7 %) | |
| Moderate | 2 (33.3 %) | 6 (35.3 %) | 20 (29.9 %) | |
| Poor | 2 (33.3 %) | 3 (17.6 %) | 11 (16.4 %) | |
| Location | 0.027 | |||
| Glottic | 3 (50.0 %) | 5 (29.4 %) | 36 (53.7 %) | |
| Supraglottic | 2 (33.3 %) | 10 (58.8 %) | 12 (17.9 %) | |
| Transglottic | 1 (16.6 %) | 2 (11.8 %) | 19 (28.4 %) | |
| Stage | 0.468 | |||
| T3 | 3 (50.0 %) | 13 (76.5 %) | 44 (65.7 %) | |
| T4 | 3 (50.0 %) | 4 (23.5 %) | 23 (34.3 %) | |
| Lymph node metastasis | 0.589 | |||
| Positive | 3 (50.0 %) | 6 (35.3 %) | 20 (29.9 %) | |
| Negative | 3 (50.0 %) | 11 (64.7 %) | 47 (70.1 %) | |
| Cigarette use (pack/year) | 57.50 (23.187) | 41.47 (14.975) | 49.03 (17.061) | 0.105 |
| Alcohol use | 0.009 | |||
| Use | 2 (33.3 %) | 5 (29.4 %) | 45 (67.2 %) | |
| Non-use | 4 (64.7 %) | 12 (70.6 %) | 22 (22.8 %) | |
| Treatment | 0.687 | |||
| Surgery | 0 (0.0 %) | 3 (17.6 %) | 6 (9.0 %) | |
| Surgery + Radiotherapy | 2 (33.3 %) | 8 (47.1 %) | 30 (44.8 %) | |
| Surgery + Chemoradiotherapy | 2 (33.3 %) | 4 (23.5 %) | 22 (32.8 %) | |
| Chemoradiotherapy | 2 (33.3 %) | 2 (11.8 %) | 9 (13.4 %) | |
| Recurrence | 0.291 | |||
| + | 3 (50.0 %) | 3 (17.6 %) | 21 (31.3 %) | |
| – | 3 (50.0 %) | 14 (82.4 %) | 46 (68.7 %) | |
| Cause of death | 0.128 | |||
| Larynx ca | 1 (33.3 %) | 3 (100.0 %) | 17 (54.8 %) | |
| Other | 2 (66.7 %) | 0 (0.0 %) | 14 (45.2 %) |